Document Type : Original Article(s)

Authors

1 Department of Community Medicine, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

2 Department of Internal Medicine, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

3 Department of Obstetrics and Gynecology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

4 Department of Health Information Technology, Amol Faculty of Paramedical Sciences, Mazandaran University of Medical Sciences, Sari, Iran

Abstract

Background: Breast cancer (BC) is the most prevalent cancer in women and the second most common cancer in the world. Two million new cases were reported in 2018. The aim of this study was to investigate the changing trend of BC in the people of Ardabil during 2003-2016.
Method: In this cross-sectional descriptive study, we analyzed BC incidence rates using population-based cancer registries stratified by city, age group, gender, and disease grading. We analyzed the collected data by statistical methods in SPSS version 21.
Results: The mean age of patients was 48.4±13.1. Of all patients, 98.5% were female, and most were aged 40-60 (56%). The most of BC cases was registered in year 2011 with the most incidence rate about 10.41 per 100000 and the most of cases with 71.5% was registered in Ardabil city. The incidence rate of BC reached from 4.13 per 100000 in 2003 to 6.93 in 2016. The annual percentage change during the study years was 4.1%.
Conclusion: Results showed that the incidence rate of BC during study years had an increasing trend in Ardabil’s people and reached from 4.13 per 100000 in year 2003 to 6.93 per 100000 in year 6.93 with Annual percentage change about 4.1%. The trend of BC incidence increased during 2003-2011 and then, decreased during 2011-2016.

Keywords

How to cite this article:

Amani F, Fouladi N, Zakeri A, Tabrizian S, Enteshari-Moghaddam A, Barzegari S. Changing trend of breast cancer in Ardabil Province, Iran by age group, grading, and gender during 2003-2016. Middle East J Cancer. 2021;12(2): 285-91. doi: 10.30476/mejc.2020.82949. 1123.